Abstract 282P
Background
Multiple Myeloma (MM) is second most common hematological malignancy characterized by uncontrolled proliferation of abnormal plasma cells in bone marrow. microRNAs are newly emerged nowadays for their involvement in post-transcriptional regulation of certain genes. Earlier, we reported overexpression of an extracellular matrix protein, Versican (VCAN) in MM especially in the stroma but its involvement in disease pathogenesis has not been reported yet. Hence, we studied the role of VCAN via its regulation by microRNAs on myeloma pathogenesis.
Methods
The molecular expression of VCAN was investigated in myeloma cell lines (RPMI8226 & U266). The antagomirs of microRNAs (miR-144 and miR-199) were then transfected into myeloma cells to investigate the effect on VCAN expression along with the effect on proliferation, apoptosis, migration and invasion of myeloma cells. In addition, signaling pathways affected by the inhibition of miR-144 and miR-199 were also identified. The functional regulation of VCAN by miR-144 and miR-199 was also confirmed by reporter luciferase assay in which VCAN 3’UTR was transfected to the myeloma cells.
Results
The expression of VCAN was found at minimal level in both the myeloma cells. The transfection of antagomirs of miR-144 and miR-199 significantly enhanced the transcript and protein levels of VCAN in myeloma cells. Further, myeloma cells parameters found to be altered in favor of disease progression such as cell proliferation, migration and invasion increased with simultaneous inhibition of apoptosis. In addition, antagomirs mediated upregulation of VCAN promote myeloma progression via activation of FAK/STAT3 signaling. Moreover, transfection of wild type VCAN 3’UTR resulted in significant decrease in luciferase activity which got restored by mutating the binding site of microRNAs.
Conclusions
miR-144 and mir-199 antagomirs mediated over-expression of VCAN promoted the myeloma pathogenesis in vitro with downstream activation of FAK and STAT3 signaling. These findings, therefore, affirm the translational importance of microRNAs which could be adopted as a mean for targeting VCAN and might emerge as an effective therapy for better management of MM in clinical settings in future.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
AIIMS, New Delhi, India.
Funding
All India Institute of Medical Sciences, Council of Scientific and Industrial Research.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
117P - Short-term and long-term outcomes of hepatectomy combined with intraoperative radiofrequency ablation for multiple colorectal liver metastases: A propensity score matching study
Presenter: Wenbai Huang
Session: Poster display session
Resources:
Abstract
119P - The impacts of dose-time-fractionation schedules on pathological complete response rate (pCR) and local recurrence (LR)
Presenter: Fu Jin
Session: Poster display session
Resources:
Abstract
120P - Platelet to lymphocyte ratio is associated with tumour localization and outcomes in patients with metastatic colorectal cancer
Presenter: Ahmet Bilici
Session: Poster display session
Resources:
Abstract
121P - Meta-analysis of three-dimensional versus two-dimensional laparoscopic surgery for rectal cancer
Presenter: Laiyuan Li
Session: Poster display session
Resources:
Abstract
127P - Outcomes based on albumin‐bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
Presenter: Stephen Chan
Session: Poster display session
Resources:
Abstract
128P - Tislelizumab in combination with chemotherapy for Chinese patients (Pts) with gastric/gastroesophageal junction cancer (GC/GEJC) or esophageal squamous cell carcinoma (ESCC)
Presenter: Yuxian Bai
Session: Poster display session
Resources:
Abstract
129P - Monitoring patient-specific mutation in ctDNA and CTC for tumour response evaluation after neoadjuvant chemotherapy in advanced gastric adenocarcinoma (NCT03425058)
Presenter: Tao Fu
Session: Poster display session
Resources:
Abstract
130P - Development of a liver cancer risk prediction model for the general population in china: A potential tool for screening
Presenter: Xiaoshuang Feng
Session: Poster display session
Resources:
Abstract
131P - Cabozantinib in Asian patients with hepatocellular carcinoma and other solid tumours: Population pharmacokinetics analysis
Presenter: Chih-Hung Hsu
Session: Poster display session
Resources:
Abstract
132P - Liposomal irinotecan (nal-IRI) plus 5-fluorouracil/levoleucovorin (5 FU/LV) vs 5-FU/LV in Japanese patients (pts) with gemcitabine-refractory metastatic pancreatic cancer (mPAC)
Presenter: Tatsuya Ioka
Session: Poster display session
Resources:
Abstract